AWI vs IONS Comparison

Armstrong World Industries Inc. designs, innovates, and manufactures ceiling and wall solutions in the Americas. The company manufactures and sources products made of numerous materials, including mineral fiber, fiberglass, metal, felt, wood, resin, wood fiber, and glass-reinforced-gypsum. It also manufactures ceiling suspension system (grid) products through a joint venture with Worthington Industries, Inc., called Worthington Armstrong Venture (WAVE). The company's reportable operating segments include Mineral Fiber, Architectural Specialties, and Unallocated Corporate. A majority of its revenue is generated from the Mineral Fiber segment, which produces suspended mineral fiber and fiberglass ceiling systems. Geographically, it derives maximum revenue from the United States.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.